INmune Bio (INMB) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 9.0% versus a loss of 62.1%. Over five years, INMB leads with a -90.2% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($60.7 million vs $51.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMB | KLRS |
|---|---|---|
| Share price | $1.86 | $2.55 |
| Market cap | $51.62M | $60.70M |
| 1-day change | +1.64% | +2.00% |
| YTD return | +17.31% | -70.38% |
| 1-year return | -8.96% | -62.06% |
| 5-year return | -90.17% | -99.51% |
| EPS (TTM) | $-0.67 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.60 | $11.88 |
| 52-week low | $1.09 | $2.35 |
| Distance from 52-week high | -28.46% | -78.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +276.34% | +633.73% |
| Average volume | 402.12K | 252.88K |
| Shares outstanding | 27.75M | 23.80M |
| Employees | 21 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed KLRS by 53.1 percentage points over the past year.
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
INMB vs KLRS FAQ
Which is bigger, INmune Bio or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $60.70M compared with $51.62M for INmune Bio (INMB).
Which stock has performed better over the past year, INMB or KLRS?
INMB returned -8.96% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are INmune Bio and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.